An Open-label, Phase 1, Single Ascending Dose-Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of a Long Acting Injectable KarXT Formulation in Participants With Schizophrenia
Latest Information Update: 24 Jul 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 24 Jul 2025 New trial record